The stock's performance on Thursday capped a significant period of growth, with share prices more than doubling over the past 12 months. Herbalife closed the session at $19.75, reflecting renewed investor confidence in the nutritional supplement provider's ability to modernize its business model and attract high-profile strategic partners.

The Pro2col Investment

The primary catalyst for the market movement was the announcement that Ronaldo has acquired a 10% equity interest in Herbalife’s Pro2col technology. According to the company, this proprietary system is designed to provide customers with tailored nutritional guidance. The $7.5 million injection from one of the world’s most recognizable athletes is a strategic move to validate Herbalife’s shift toward data-driven, personalized health solutions.

Revenue Growth and Guidance

Financial results for the fourth quarter further bolstered the stock's trajectory. Revenue climbed 6.3% to $1.28 billion, comfortably exceeding the $1.24 billion anticipated by Wall Street analysts. This growth comes as the company continues to streamline operations and expand its digital footprint.

Looking ahead, management issued a revenue guidance range of 1% to 6% for the 2026 fiscal year. While the forecast is broad, it brackets the 3% growth currently projected by analysts, suggesting a stable outlook as the company integrates its new technology-focused investments.